Physician profile
Tim E Baker
NPI 1760596134
$817.48
in general payments reported to CMS, 2019-2025
14 companies · $47.47 in 2025
The $47.47 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $259 · 2020: $70.43 · 2021: $239 · 2022: $76.57 · 2023: $126 · 2025: $47.47.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $173.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $173.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $243.17 | 2021-2025 | Ubrelvy, Qulipta |
| Merck Sharp & Dohme LLC | $129.18 | 2019-2021 | |
| Astellas Pharma US INC | $85.00 | 2021 | |
| Sanofi-Aventis U.S. LLC | $80.00 | 2021 | |
| Novo Nordisk INC | $79.97 | 2019-2025 | Ozempic, Rybelsus |
| Boehringer Ingelheim Pharmaceuticals, INC. | $49.65 | 2019-2020 | |
| Lilly USA, LLC | $41.03 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $28.07 | 2019 | |
| Pfizer INC. | $16.58 | 2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $16.07 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $13.46 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $12.16 | 2019 | |
| Glaxosmithkline, LLC. | $11.94 | 2019 | |
| Allergan, INC. | $11.20 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tim Baker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.